Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Vidal, Alessandra Teixeira | - |
Autor(es): dc.creator | Guimarães, Homero Nogueira | - |
Autor(es): dc.creator | Paula, Danielle Cristiane Correa de | - |
Autor(es): dc.creator | Frezard, Frederic Jean Georges | - |
Autor(es): dc.creator | Barcellos, Neila Marcia Silva | - |
Autor(es): dc.creator | Guimarães, Andrea Grabe | - |
Data de aceite: dc.date.accessioned | 2019-11-06T13:24:15Z | - |
Data de disponibilização: dc.date.available | 2019-11-06T13:24:15Z | - |
Data de envio: dc.date.issued | 2012-07-10 | - |
Data de envio: dc.date.issued | 2012-07-10 | - |
Data de envio: dc.date.issued | 2010 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/123456789/1052 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/554666 | - |
Descrição: dc.description | Aims: The purpose of the present work was to investigate the ability of pyridostigmine encapsulated in longcirculating liposomes, to protect against ECG(electrocardiogram) alterations induced by sympathetic stimulation in rats. Main methods: The encapsulation of pyridostigmine was carried out by freeze–thaw and extrusion. Blood pressure and ECG (limb lead II) were monitored in anaesthetized male Wistar rats. The formulation containing pyridostigmine was intravenously administrated in 0.1, 0.3 and 1.0 mg/kg doses, and sympathetic stimulation was conducted by administration of 1 or 3 μg of noradrenaline (NA) after 1, 2, 4 or 6 h. The obtained cardiovascular parameters were compared to animals that received intravenous injection of pyridostigmine in free form or saline. Key findings: After saline, NA induced a significant increase in QT interval (22.3% after 3.0 μg). Previous administration of free pyridostigmine significantly prevented the increase of QT interval after sympathetic stimulation and the most prominent effect was observed after 1h for the dose of 0.3 mg/kg (6.8% after 3.0 μg of NA) and was no longer observed after 2 h of the treatment. On the other hand, the maximum effect of pyridostigmine in liposomal formulation preventing QT interval increasewas observed 2 h after treatment (9.7% after 3.0 μg of NA) and was still present until 6 h when 1 mg/kg was previous administrated. Significance: The results of the present study, beyond to confirm the cardioprotective action of pyridostigmine, suggest that liposomal pyridostigmine may be a potential therapeutic alternative to prevent cardiovascular disturbances resulting from sympathetic hyperactivity. | - |
Idioma: dc.language | en | - |
Direitos: dc.rights | O Periódico Life Sciences concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 500791718. | - |
Palavras-chave: dc.subject | QT interval, ECG | - |
Palavras-chave: dc.subject | Rats | - |
Palavras-chave: dc.subject | Pyridostigmine | - |
Palavras-chave: dc.subject | Liposomes | - |
Palavras-chave: dc.subject | Sympathetic stimulation | - |
Título: dc.title | Prolonged cardioprotective effect of pyridostigmine encapsulated in liposomes. | - |
Aparece nas coleções: | Repositório Institucional - UFOP |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: